🇺🇸·5h agoIndustry
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Publisher
M
Merck & Co. (MSD) News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck & Co. (MSD) News
Scope: Industry
Related coverage
More related coverage
Hyman, Phelps & McNamara (FDA Law)·5h ago
ACI’s 2nd Annual Summit on GLP-1 Law & Policy
Sumitomo Pharma·7h ago
Notice Regarding Determination of Issue Price, Selling Price and Other Matters
Menicon·14h ago
Scleral lens “Time XL” acquires approval in China - New option for patients with irregular cornea available in the Chinese market -
Otsuka Holdings RSS·15h ago